The kynurenine pathway: Towards metabolic equilibrium by Clarke, Gerard et al.
 
 
 
 
Clarke, G., Stone, T. W. and Schwarcz, R. (2017) The kynurenine pathway: 
Towards metabolic equilibrium. Neuropharmacology, 112(part B), pp. 235-
236. (doi:10.1016/j.neuropharm.2016.08.029) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/124325/ 
     
 
 
 
 
 
 
Deposited on: 12 October 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Editorial for the Special Issue on Kynurenines in Neuropharmacology 
Eds. Clarke, G., Stone, T. W., and Schwarcz, R 
 
 
 
The Kynurenine Pathway: Towards Metabolic Equilibrium 
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Metabolism of tryptophan along the kynurenine pathway yields multiple metabolites that 
collectively exhibit both a rich pharmacology and a broad neurobiological significance 
(Schwarcz et al. 2012).This  includes not just neurotoxic and neuroprotective metabolites that 
exert their influence via opposing action at NMDA receptors but also molecules with activity 
at metabotropic glutamate receptor subtypes, the aryl hydrocarbon receptor and specific G-
protein coupled receptors (GPCRs) (Stone et al. 2013). Despite the therapeutic possibilities 
arising from this extensive pharmacological repertoire, kynurenines have struggled to reach a 
status in the scientific consciousness comparable with other tryptophan metabolites such as 
serotonin and melatonin. The growing realisation that the sphere of influence of dysregulated 
metabolism extends to most fundamental aspects of brain function with manifestations 
possible across the life span has seen this imbalance somewhat rectified. Now that these 
metabolites are no longer neglected, it is not surprising that altered metabolism along this 
pathway has been associated with numerous psychiatric and neurological disorders. Indeed, 
the immunoresponsive and stress-reactive nature of kynurenine pathway enzymes has 
stimulated biomarker studies and brought into focus a number of appealing therapeutic 
targets of relevance across a wide swathe of pathologies. The pathway still holds much 
unlocked potential and although there is now a solid grasp of many of its features and 
nuances, there remain understudied metabolites and enzymes as well as the capacity for 
ongoing research to reveal new layers of complexity and provide fresh insights. 
This special issue of Neuropharmacology is an effort to provide a collection of articles to 
illustrate the research challenges and opportunities provided by our mounting but still 
incomplete knowledge of kynurenine pathway metabolism. Schwarcz and Stone (ref) chart 
the rise of the kynurenines from relative obscurity to their current prominence. This overview 
also illuminates the knowledge gaps to be bridged, and the pitfalls and promise inherent in 
this complex area of research. Clearly, an understanding of kynurenine pathway metabolism 
is contingent on a solid appreciation of the factors influencing the availability of tryptophan 
under both normal and pathological conditions (Badawy 2015). Fujigaki and colleagues 
(Fujigaki et al. 2016) further elaborate on the mechanisms that regulate kynurenine enzyme 
expression and activity with an emphasis on cell-type specific features of the metabolic 
cascade. 
The implications of altered metabolism of tryptophan along the kynurenine pathway are 
manifold and may manifest across the life span. Notarangelo and Pocivavsek (Notarangelo 
and Pocivavsek 2016) emphasise the important role of fluctuations in these neuroactive 
metabolites during critical neurodevelopmental windows, visible particularly in cognitive 
impairments expressed in adulthood following kynurenic acid modulation during gestation or 
postnatally. The role of the immune system in activating kynurenine pathway metabolism has 
implications for numerous disorders, particularly when viewed through the lens of infection-
mediated alterations in behaviour and the links between immune system malfunction and 
psychopathology (Strasser et al. 2016). Equally, activation of the kynurenine pathway by 
glucocorticoids is an important factor for many stress-related disorders (O'Farrell and Harkin 
2015). The possibility that kynurenine pathway metabolism could be implicated as a 
neurobiological factor underpinning suicidality has also received attention (Bryleva and 
Brundin 2016). It is also important to bear in mind that some kynurenines participate in redox 
reactions and this may have repercussions for critical biological functions that malfunction in 
relevant pathologies (Gonzalez Esquivel et al. 2016). 
As research advances in this area and moves beyond more general concepts of pathway 
activation, it is clear that certain metabolites of the kynurenine pathway may hold special 
relevance for specific disorders. For example, much research now associates the 
accumulation of quinolinic acid with Amyotrophic lateral sclerosis (ALS) (Lee et al. 2016). 
In tandem, information about an expanding range of molecular targets continues to emerge 
for previously understudied metabolites including cinnabarinic acid as an orthosteric agonist 
of mGlu4 receptors and the activation of mGlu2 and mGlu3 receptors by xanthurenic acid 
(Fazio et al. 2016). Given the important role of metabotropic glutamate  receptors in the CNS 
as well as in peripheral and non-neural tissues, this is a promising avenue of investigation (for 
review see: (Julio-Pieper et al. 2011).  
These and other developments highlighting the therapeutic potential in targeting kynurenine 
pathway metabolism have encouraged the extension of research on the kynurenine pathway 
to other neurological disorders such as multiple sclerosis as well as HIV-associated 
neurocognitive disorders (Lovelace et al. 2016). The CNS impact of parasitic diseases, such 
as malaria and toxoplasmosis, has also been considered in the context of their impact on 
kynurenine production (Hunt et al. 2016). Finally, Kennedy at al (Kennedy et al. 2016) 
evaluate the emerging research supporting a role for the gut microbiota in the regulation of 
kynurenine pathway metabolism.  
Taken together, the breadth of these topics should make clear our motivation to put the 
kynurenine pathway under the spotlight in this special issue. The capacity of the kynurenines 
to surprise us should not be underestimated and we hope that the insights in this compilation 
of articles provides both stimulus and direction for ongoing research efforts and new 
researchers in the field. Now that consequences of the dysregulation of kynurenine pathway 
metabolism is more fully appreciated and as the range of activity of the kynurenines is further 
teased apart, we can start to envisage the benefits of interventions that move us back towards 
a metabolic equilibrium. 
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